Integrated Multi-Omics Analysis Identified PTPRG and CHL1 As Key Regulators of Immunophenotypes in Clear Cell Renal Cell Carcinoma(ccRCC)

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Apr 18

PMID 35433461

Authors

Xing Zeng

Le Li

Zhiquan Hu

Dan Peng

Affiliations

Soon will be listed here.

Abstract

Despite the increasing importance and status of immune checkpoint blockade (ICB), little is known about the underlying molecular mechanisms determining the target clear cell renal cell carcinoma (ccRCC) population. In this study, we screened out 6 immune cells strongly correlated with expression levels of PD-L1 and IFN-γ based on the ccRCC samples extracted from GSE and TCGA data sets. By performing unsupervised clustering and lasso regression analysis, we grouped the ccRCC into 4 clusters and selected the two most distinct sub-clusters for further investigation-cluster A1 and B1. Next, we compared the two clusters in terms of mRNA, somatic mutations, copy number variations, DNA methylation, miRNA, lncRNA and constructed the differentially expressed genes (DEGs) hub by combing together the previous results at levels of DNA methylation, miRNA, and lncRNA. PTPRG and CHL1 were identified as key nodes in the regulation hub of immunophenotypes in ccRCC patients. Finally, we established the prognosis model by using Lasso-Cox regression and Kaplan-Meier analysis, recognizing WNT2, C17orf66, and PAEP as independent significant risk factors while IRF4 as an independent protective factor.

Citing Articles

The multiple roles of interferon regulatory factor family in health and disease.

Wang L, Zhu Y, Zhang N, Xian Y, Tang Y, Ye J Signal Transduct Target Ther. 2024; 9(1):282.

PMID: 39384770 PMC: 11486635. DOI: 10.1038/s41392-024-01980-4.

Comprehensive Analysis of Angiogenesis and Ferroptosis Genes for Predicting the Survival Outcome and Immunotherapy Response of Hepatocellular Carcinoma.

Wang P, Kong G J Hepatocell Carcinoma. 2024; 11:1845-1859.

PMID: 39364435 PMC: 11448465. DOI: 10.2147/JHC.S483647.

Metabolic classifications of renal cell carcinoma reveal intrinsic connections with clinical and immune characteristics.

Li L, Chao Z, Waikeong U, Xiao J, Ge Y, Wang Y J Transl Med. 2023; 21(1):146.

PMID: 36829161 PMC: 9960222. DOI: 10.1186/s12967-023-03978-y.

A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis.

Li R, Chen W, Lu C, Li X, Chen X, Huang G Front Oncol. 2023; 12:1076303.

PMID: 36727070 PMC: 9885090. DOI: 10.3389/fonc.2022.1076303.

Prognosis and pain dissection of novel signatures in kidney renal clear cell carcinoma based on fatty acid metabolism-related genes.

Ding R, Wei H, Jiang X, Wei L, Deng M, Yuan H Front Oncol. 2022; 12:1094657.

PMID: 36568252 PMC: 9780486. DOI: 10.3389/fonc.2022.1094657.

References

Arimura Y, Yagi J . Comprehensive expression profiles of genes for protein tyrosine phosphatases in immune cells. Sci Signal. 2010; 3(137):rs1. DOI: 10.1126/scisignal.2000966. View

Antony J, Zanini E, Kelly Z, Tan T, Karali E, Alomary M . The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. EMBO Rep. 2018; 19(8). PMC: 6073217. DOI: 10.15252/embr.201745670. View

Leshchynska I, Sytnyk V, Richter M, Andreyeva A, Puchkov D, Schachner M . The adhesion molecule CHL1 regulates uncoating of clathrin-coated synaptic vesicles. Neuron. 2006; 52(6):1011-25. DOI: 10.1016/j.neuron.2006.10.020. View

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

Yamamoto K, Makino T, Sato E, Noma T, Urakawa S, Takeoka T . Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer. Cancer Sci. 2020; 111(4):1103-1112. PMC: 7156837. DOI: 10.1111/cas.14328. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Tang H, Jiang L, Zhu C, Liu R, Wu Y, Yan Q . Loss of cell adhesion molecule L1 like promotes tumor growth and metastasis in esophageal squamous cell carcinoma. Oncogene. 2019; 38(17):3119-3133. DOI: 10.1038/s41388-018-0648-7. View

Cheng Y, Zhang X, Wang Z, Wang J . Reconstruction of Immune Microenvironment and Signaling Pathways in Endometrioid Endometrial Adenocarcinoma During Formation of Lymphovascular Space Involvement and Lymph Node Metastasis. Front Oncol. 2020; 10:595082. PMC: 7756104. DOI: 10.3389/fonc.2020.595082. View

Weber R, Meister M, Muley T, Thomas M, Sultmann H, Warth A . Pathways regulating the expression of the immunomodulatory protein glycodelin in non‑small cell lung cancer. Int J Oncol. 2018; 54(2):515-526. PMC: 6317686. DOI: 10.3892/ijo.2018.4654. View

10.

Biton J, Mansuet-Lupo A, Pecuchet N, Alifano M, Ouakrim H, Arrondeau J . , and Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. Clin Cancer Res. 2018; 24(22):5710-5723. DOI: 10.1158/1078-0432.CCR-18-0163. View

11.

Zhao W, Zhao F, Yang K, Lu Y, Zhang Y, Wang W . An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade. J Cell Biochem. 2019; 120(8):13330-13341. DOI: 10.1002/jcb.28607. View

12.

Senbabaoglu Y, Gejman R, Winer A, Liu M, Van Allen E, de Velasco G . Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016; 17(1):231. PMC: 5114739. DOI: 10.1186/s13059-016-1092-z. View

13.

Mulder W, Ochando J, Joosten L, Fayad Z, Netea M . Therapeutic targeting of trained immunity. Nat Rev Drug Discov. 2019; 18(7):553-566. PMC: 7069501. DOI: 10.1038/s41573-019-0025-4. View

14.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

15.

Wu Z, Chen Q, Qu L, Li M, Wang L, Mir M . Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. Eur Urol. 2022; 81(4):414-425. DOI: 10.1016/j.eururo.2022.01.028. View

16.

Miao D, Margolis C, Gao W, Voss M, Li W, Martini D . Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018; 359(6377):801-806. PMC: 6035749. DOI: 10.1126/science.aan5951. View

17.

Saloura V, Izumchenko E, Zuo Z, Bao R, Korzinkin M, Ozerov I . Immune profiles in primary squamous cell carcinoma of the head and neck. Oral Oncol. 2019; 96:77-88. PMC: 7893610. DOI: 10.1016/j.oraloncology.2019.06.032. View

18.

Motzer R, Alekseev B, Rha S, Porta C, Eto M, Powles T . Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021; 384(14):1289-1300. DOI: 10.1056/NEJMoa2035716. View

19.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

20.

Della Peruta M, Martinelli G, Moratti E, Pintani D, Vezzalini M, Mafficini A . Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. Cancer Res. 2010; 70(21):8896-906. DOI: 10.1158/0008-5472.CAN-10-0258. View